Arcturus Therapeutics Holdings announced that the Clinical Trial Application CTA for ARCT-032, an inhaled investigational mRNA medicine to treat cystic fibrosis CF , received approval to proceed into a Phase 1 First-in-Human study in New Zealand. "Arcturus continues to progress ARCT-032, a potential mRNA medicine for people with cystic fibrosis regardless of their underlying mutation type, through the approval of a CTA to proceed into First-in-Human studies," said Joseph Payne, President and CEO of Arcturus Therapeutics. "We believe the advantages driven by our proprietary LUNAR( delivery technology, advanced mRNA purification processes, and manufacturing know-how may allow ARCT-032 to restore healthy CFTR protein in the lungs of people with CF, including those that currently do not have effective treatment options. Preclinical data shared at the recent North American Cystic Fibrosis Conference demonstrated robust expression and functional restoration of CFTR in human bronchial epithelial cells from CF donors, providing additional support for the advancement of ARCT-032 into clinical development."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARCT:
